Jazz Seeks To Augment Rare Cancer Portfolio With Chimerx Buyout
Jazz will pay $935m to acquire Chimerx and its drug for a rare form of brain cancer that has an FDA approval date in August. Dordaviprone might pair well with Ziihera, analysts said.
Jazz will pay $935m to acquire Chimerx and its drug for a rare form of brain cancer that has an FDA approval date in August. Dordaviprone might pair well with Ziihera, analysts said.